Primary and Surrogate Endpoints in Clinical Trials: Implementation and Challenges in Daily Practice

The choice of an endpoint can really change the way a treatment is administered or approved for use on patients. And in the future, we will see much more data on quality of life, and trials will probably also work on validating surrogate endpoints and biomarkers.  In this TJ Talks dedicated to the…

Pharmaco-prevention in Breast Cancer: a strategy to halve the incidence of a potentially fatal disease

Pharmaco-prevention of breast cancer is an evidence-based strategy that uses drugs to reduce the risk of disease in high-risk women. However, the use of this strategy remains modest due to concerns about toxicity, low awareness and difficulties in patient selection. In this TJ Talks podcast, toget…

The last journey: the invisible needs of migrant patients between palliative care and the need for protection

Stories of foreign cancer patients who ask to return to their country at the end of their lives: their deep desire to see their loved ones one last time is intertwined with medical, legal and financial issues that seem insurmountable. In this TJ Talks, Dr Sergio Defendi, director of Palliative Care…

The last journey: il bisogno invisibile dei pazienti migranti fra cure palliative e necessità di tutela

Storie di pazienti oncologici stranieri che chiedono di tornare nel loro Paese per il fine vita: attorno al desiderio profondo di rivedere ancora una volta i propri cari si intrecciano questioni mediche, legali, finanziarie che sembrano insormontabili. A parlarne in questo episodio di TJ Talks è il…

The role of real-world trials and single-arm trials in the drug approval process

Looking forward to the future, the trends and challenges regarding the increasing utilization of real-world data and single-arm trials in the oncology drug approval pathway by European Medicines Agency (EMA) is very important, especially in the context of personalized medicine that will become the …

Oncologia di precisione: approccio multidisciplinare e intelligenza artificiale per terapie personalizzate

Le parole del prof. Paolo Marchetti restituiscono il quadro complesso dell’oncologia di precisione con il ritmo epico delle grandi imprese di frontiera.  E’ lui - Professore Ordinario di Oncologia Medica dell’Università degli Studi di Roma “La Sapienza”, Direttore Scientifico di IDI-IRCCS, Presiden…

Precision Oncology: Multidisciplinary Approach and Artificial Intelligence for Personalized Therapies

In this episode of TJ Talks, the guest is Professor Paolo Marchetti, a well-known expert in precision oncology in Italy, Full Professor of Medical Oncology at the University of Rome "La Sapienza", Scientific Director of IDI-IRCCS, President of the Foundation for Personalized Medicine and promoter o…

Liquid biopsy and molecularly driven therapies for colorectal cancer: current and future applications in precision oncology

If we were to stop at a first glance, the use of liquid biopsy would be limited in the clinical practice of colorectal cancer to cases where tumour tissue is unavailable or insufficient. In reality, we are at the beginning of a pathway where the true potential of liquid biopsy is developing rapidly…

Bioinformatics horizons: future trends and opportunities for young scientists in Italy

The field of bioinformatics is rapidly evolving, shaping the future of biomedical research and precision medicine. From cutting-edge advancements in computational biology to AI-driven solutions, what will the landscape look like in Italy in the coming years, and what opportunities will emerge for y…

Drug resistance overcoming: insights from the preclinical world

Drug resistance is a major challenge in oncology and genetically-engineered mouse models represent powerful tools to identify new approaches for its overcoming. In this TJ Talks podcast, Prof Paola Perego, Pharmacology Section Editor of Tumori Journal and Adjunct Professor at the University of Ins…